All In MedTech

FDA Clearance Tracker · P830061-S129

CAPSURE SENSE MRI SURESCAN LEAD MODELS 4074 AND 4574.

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 12, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 12, 2016

Approved

Time to decision

180 days

Received Apr 15, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P830061-S129
Device name
CAPSURE SENSE MRI SURESCAN LEAD MODELS 4074 AND 4574.
Applicant location
Mounds View, MN
Received
Apr 15, 2016
Decided
Oct 12, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P830061

Device type

Device class
Class III

Every decision under product code NVN

FDA's approval statement

As written in FDA's record.

Approval for the 1.5T/3T MR Conditional Evera MRI and Visia AF MRI DF-1 ICDs, 1.5T/3T MR Conditional Labeling of approved Sprint Quattro Secure Lead Models 6935 and 6947, and 3T MR Conditional labeling of Visia AF MRI DF4 ICDs.

Source documents

Other decisions for Medtronic Cardiac Rhythm Disease Management

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.